Atacana Group > Resources Center > Reports > Antibacterial Vaccines Catalysts
Dark Mode

Antibacterial Vaccines Catalysts

Antibacterial Vaccines Catalysts
Atacana Group

Explore the future of the global antibacterial vaccine market, anticipating growth from $22B to $40B by 2030, unveiling a lucrative landscape ripe for innovation.

Major regulatory advancements in the US and EU put Merck, GSK, and Sanofi at the forefront to grab a share of the lucrative antibacterial vaccine market.

Pfizer’s imminent launch of an adolescent vaccine hints at a strategic maneuver to fortify its vaccine portfolio.

Ready to delve deeper into the future of antibacterial vaccines?

Get a copy below.


Vaccines 2024 & 2025 Catalysts Report